- Animal Brain & Cell Adaptive Lab: we have developed a project to understand the relationship between depression and migraine.
- We have received several project and personal grants to be able to start studying the function of glia in animal migraine models.
- Gene-Environment Lab: we have continued to work on our epigenetic, transcriptomic and molecular research, which is focused on disease diagnosis and target-driven therapeutics
- Sense, Rhythm & Connectivity lab: we have focused on analyzing and publishing experiments which were done in the last 3 years of research.
- Clinical MAB program: we have worked on several clinical trials and 5 large investigator-driven projects.
- We have participated in 31 industry-driven clinical trials, including 293 patients in children and adults.
eCORE
- Brain & Mind and Behaviour
- Chronic, Prevalent Diseases & Aging
- Woman & Child Health & Rare Diseases
Team
Group Leader
Patricia Pozo Rosich
Principal Investigator (PI)
Marta Torres-Ferrus, Marta Vila-Pueyo
Researchers
Edoardo Caronna, Victor J Gallardo, Alicia Alpuente, Nara Ikumi
PhD Students
Joana Rosell Miami, Otilia Gliga, Rut Mas de les Valls
Lab Technicians
Laila Asskour
Nursing and Technical Staff
Eulalia Giné Ciprés, Raquel Lastra, Estefania Muñoz
Publications
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2023:S0140-6736(23)01049-8
DOI: 10.1016/S0140-6736(23)01049-8
IF: 168.9
Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P
Patterns of response to anti-CGRP monoclonal antibodies during the first 6-months of treatment in resistant migraine patients: impact on outcome
Eur J Neurol 2023;30:1937-1944
DOI: 10.1111/ene.15816
IF: 5.1
Marti-Marca A, Vila-Ballo A, Cerda-Company X, Ikumi N, Torres-Ferus M, Caronna E, Gallardo VJ, Aluente A, Torralba Cuello M, Soto-Faraco S, Pozo-Rosich P.
Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using pattern-reversal task
The Journal of Headache and Pain 2023;24:104
DOI: 10.1186/s10194-023-01618-w
IF: 7.4
Gallardo VJ, Gomez-Galvan JB, Asskour L, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P.
A study of differential microRNA expression profile in migraine: the microMIG exploratory study
J Headache Pain 2023;24(1):11
DOI: 10.1186/s10194-023-01542-z
IF: 7.4
Vila-Pueyo M, Cuenca-Leon E, Queiros AC, Kulis M, Sintas C, Cormand B, Martin-Subero JI, Pozo-Rosich P, Fernandez-Castillo N, Macaya A.
Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization.
Cephalalgia 2023;43: 3331024221146317.
DOI: 10.1177/03331024221146317
IF: 5
Projects
BIOMIGA:un abordaje multidisciplinar para la identificacion de biomarcadores en migraña: estudio de prueba de concepto basado en la estratificación de respondedores a anticuerpos monoclonales contra el CGRP
Principal Investigator: Patricia Pozo-Rosich
Agency: EraNET Neuron
Funding: 100,000 €
Period: 2020-2023
AhEAD:Algoritmo de predicción de Eficacia de respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos
Principal Investigator: Patricia Pozo-Rosich
Agency: AES - Instituto Salud Carlos III
Funding: 85,000 €
Period: 2019-2023
FAST:Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión
Principal Investigator: Patricia Pozo-Rosich
Agency: AES: Instituto de Salud Carlos III
Funding: 90,000 €
Period: 2022-2025
MAMBO: BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña
Principal Investigator: Marta Torres-Ferrus
Agency: AES: Instituto de Salud Carlos III
Funding: 81,000 €
Period: 2022-2025
PREDIMIGRAINE:Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas
Principal Investigator: Patricia Pozo-Rosich
Agency: ISCIII - IMPACT
Funding: 179,500 €
Period: 2023-2026
